Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer

Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer

Immune checkpoint inhibitors have become the standard of care in the treatment of metastatic non-small-cell lung cancer (NSCLC). The combination of nivolumab plus ipilimumab and chemotherapy has been shown to improve outcomes in terms of overall survival (OS) and progression-free survival (PFS). The...

Full description

Bibliographic Details
Main Authors: Walid Shalata, Alexander Yakobson, Yulia Dudnik, Forat Swaid, Mohammad Sheikh Ahmad, Ashraf Abu Jama, Ahron Yehonatan Cohen, Abed Agbarya
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Biomedicines
Subjects:
chemotherapy
ipilimumab
nivolumab
metastasis
non-small-cell lung cancer (NSCLC)
progression free survival
Online Access:https://www.mdpi.com/2227-9059/11/9/2438

Internet

https://www.mdpi.com/2227-9059/11/9/2438

Similar Items